Philip Greenland

Philip Greenland

Auto-generated profile, based on publicly available information

Philip Greenland

Northwestern University Feinberg School of Medicine

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in JACC
Verified
Journal Article
Closed access
PGPhilip Greenland
Philip Greenland
MBMichael J. Blaha
Michael J. Blaha
MBMatthew J. Budoff
Matthew J. Budoff
RERaimund Erbel
Raimund Erbel
KWKarol E. Watson
Karol E. Watson

20 August 2003 in JAMA
Verified
Journal Article
Closed access
PDF file
PGPhilip Greenland
Philip Greenland
MKMaria Deloria Knoll
Maria Deloria Knoll
JSJeremiah Stamler
Jeremiah Stamler
JNJames D. Neaton
James D. Neaton
ADAlan R. Dyer
Alan R. Dyer
PWPeter W. Wilson
Peter W. Wilson
Research from JAMA — Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events — ContextA frequently cited concept is that individual major risk factors for coronary heart disease (CHD) are absent in many patients (perhaps >50%) with CHD. However, prior studies have not systematically evaluated the extent to which CHD patients have previous exposure to at least 1 risk factor, including diabetes, cigarette smoking, or clinically elevated levels of cholesterol or blood pressure.ObjectiveTo determine the frequency of exposure to major CHD risk factors.Design, Setting, and ParticipantsThree prospective cohort studies were included: the Chicago Heart Association Detection Project in Industry, with a population sample of 35 642 employed men and women aged 18 to 59 years; screenees for the Multiple Risk Factor Intervention Trial, including 347 978 men aged 35 to 57 years; and a population-based sample of 3295 men and women aged 34 to 59 years from the Framingham Heart Study (FHS). Follow-up lasted 21 to 30 years across the studies.Main Outcome MeasuresFatal CHD in all cohorts and nonfatal myocardial infarction (MI) in the FHS, compared by exposure to major CHD risk factors, defined as total cholesterol of at least 240 mg/dL (≥6.22 mmol/L), systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, cigarette smoking, and diabetes. Participants were stratified by sex and age (18-39 vs 40-59 years).ResultsFor fatal CHD (n = 20 995), exposure to at least 1 clinically elevated major risk factor ranged from 87% to 100%. Among those aged 40 to 59 years at baseline with fatal CHD (n = 19 263), exposure to at least 1 major risk factor ranged from 87% to 94%. For nonfatal MI, prior exposure was documented in 92% (95% CI, 87%-96%) (n = 167) of men aged 40 to 59 years at baseline and in 87% (95% CI, 80%-94%) (n = 94) of women in this age group.ConclusionsAntecedent major CHD risk factor exposures were very common among those who developed CHD, emphasizing the importance of considering all major risk factors in determining CHD risk estimation and in attempting to prevent clinical CHD. These results challenge claims that CHD events commonly occur in persons without exposure to at least 1 major CHD risk factor.

9 October 2001 in Circulation
Verified
Journal Article
Closed access
PDF file
PGPhilip Greenland
Philip Greenland
SJSidney C. Smith Jr
Sidney C. Smith Jr
SGScott M. Grundy
Scott M. Grundy

25 August 2021 in Circulation Research
Verified
Journal Article
Closed access
PDF file
BJBrian Joyce
Brian Joyce
TGTao Gao
Tao Gao
YZYinan Zheng
Yinan Zheng
JMJiantao Ma
Jiantao Ma
SHShih-Jen Hwang
Shih-Jen Hwang
DLDonald M Lloyd-Jones
Donald M Lloyd-Jones
Rationale: Epigenetic aging is a novel measure of biological age, reflecting exposures and disease risks independent of chronological age. It may serve as a useful biomarker of cardiovascular health (CVH) or cardiovascular disease risk for early detection or prevention. Objective: To examine associations between GrimAge acceleration (GrimAA), a measure of epigenetic aging calculated from the residuals of GrimAge regressed on chronological age, and 2 repeated CVH measures: a full score for the AHA Life’s Simple 7 (diet, smoking, physical activity, body mass index, blood pressure, total cholesterol, and glucose) and a clinical CVH score (body mass index, blood pressure, cholesterol, and glucose). Methods and Results: We used Illumina array DNA methylation data from 2 prospective cohort studies, the CARDIA study (Coronary Artery Risk Development in Young Adults) and FHS (Framingham Heart Study), to calculate GrimAA and model associations with CVH. CARDIA randomly selected 1118 participants for assays at Y15 (2000–2001; mean age, 40 years) and Y20 (2005–2006); in FHS, 2106 Offspring participants had DNA methylation measured at exam 8 (2005–2008; mean age, 66 years). We examined multiple cross-sectional and longitudinal models of GrimAA and each CVH score measured at CARDIA Y0 to Y20 and FHS exams 7 to 8. In CARDIA, clinical CVH score from Y0 to Y20 was associated with Y15 and Y20 GrimAA (β range, −0.41 to −0.21 years per 1-point increase in CVH; P range, <0.01–0.01), as was full score (β range, −0.65 to −0.67 years; P <0.01 for all). These findings were validated in FHS (clinical score β range, −0.51 to −0.54 years; full score β range, −0.76 to −0.83 years; P <0.01 for all). Conclusions: Our data demonstrate that faster GrimAA is associated with the loss of CVH from young age. Epigenetic age may be a useful biomarker of cardiovascular disease risk and provides biological insight into the role of epigenetic mechanisms linking age-related CVH loss and cardiovascular disease.

1 May 2003 in The American Journal of Cardiology
Verified
Journal Article
Closed access
PGPhilip Greenland
Philip Greenland
XXXiaoyuan Xie
Xiaoyuan Xie
KLKiang Liu
Kiang Liu
LCLaura Colangelo
Laura Colangelo
YLYoulian Liao
Youlian Liao
JSJeremiah Stamler
Jeremiah Stamler

3 August 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
Yoshihiro TanakaYoshihiro Tanaka
Yoshihiro Tanaka
NSNilay S. Shah
Nilay S. Shah
RPRod Passman
Rod Passman
PGPhilip Greenland
Philip Greenland
DLDonald M Lloyd-Jones
Donald M Lloyd-Jones
SKSadiya S. Khan
Sadiya S. Khan
Background: Prevalence of atrial fibrillation (AF) continues to increase and is associated with significant cardiovascular morbidity and mortality. To inform prevention strategies aimed at reducing the burden of AF, we sought to quantify trends in cardiovascular mortality related to AF in the United States. Methods and Results: We performed serial cross‐sectional analyses of national death certificate data for cardiovascular mortality related to AF, whereby cardiovascular disease was listed as underlying cause of death and AF as multiple cause of death among adults aged 35 to 84 years using the Centers for Disease Control and Prevention's Wide‐Ranging Online Data for Epidemiologic Research. We calculated age‐adjusted mortality rates per 100 000 population and examined trends over time, estimating average annual percentage change using the Joinpoint Regression Program. Subgroup analyses were performed by race‐sex and across 2 age groups (younger: 35–64 years; older: 65–84 years). A total of 276 373 cardiovascular deaths related to AF were identified in the United States between 2011 and 2018 in decedents aged 35 to 84 years. Age‐adjusted mortality rate increased from 18.0 (95% CI, 17.8–18.2) to 22.3 (95% CI, 22.0–22.4) per 100 000 population between 2011 and 2018. The increase in age‐adjusted mortality rate (average annual percentage change) between 2011 and 2018 was greater among younger decedents (7.4% per year [95% CI, 6.8%–8.0%]) compared with older decedents (3.0% per year [95% CI, 2.6%–3.4%]). Conclusions: Cardiovascular deaths related to AF are increasing, especially among younger adults, and warrant greater attention to prevention earlier in the life course.